Update on "3 in 1" medical advances for chronic patients

The event marks the beginning of a key project, opening an important step in the journey of long-term cooperation, aiming to improve the quality of treatment for patients and contribute to improving the health care system in Vietnam.

At the event, representatives of FPT Long Chau and AstraZeneca Vietnam updated in-depth medical knowledge and consulting skills for pharmacists throughout the system, as well as raised awareness of health care among patients, thereby promoting compliance with treatment regimens, contributing to spreading practical values ​​to the community.

The year 2025 marks a special milestone in the 10-year journey of using the active ingredient dapagliflozin researched and produced by AstraZeneca in the Vietnamese market.

This therapy continues to be approved by the US Food and Drug Administration (FDA) for a new indication in the treatment of chronic kidney disease in addition to two groups of type 2 diabetes and heart failure.

This medical advance confirms the outstanding value of a treatment solution that can effectively impact three chronic diseases that have a major impact on public health, including diabetes, heart failure and chronic kidney disease.

According to medical experts, cardiovascular-renal-metabolic diseases are closely related to each other, often exist simultaneously and can aggravate the remaining pathological condition. Therefore, the treatment of chronic kidney disease will not be for a single disease but requires simultaneous treatment and protection of all three diseases. This direction also opens up opportunities to comprehensively improve the health of millions of patients, contributing to reducing the burden on the country's health system.

Mr. Atul Tandon - General Director of Astrazeneca Vietnam shared: AstraZeneca's mission is driven by a passion to understand and address patient needs, discover and develop innovative treatments, and strengthen close collaboration with local partners to improve the quality of life of patients.

Ms. Nguyen Do Quyen, Executive Director of FPT Long Chau pharmacy and vaccination system.

Ms. Nguyen Do Quyen, Deputy General Director of FPT Retail and Executive Director of FPT Long Chau pharmacy and vaccination system, said that after 4 years of strategic cooperation, a series of community activities have been implemented, training thousands of pharmacists and connecting with leading medical experts. With more than 16,000 pharmacists serving 26 million customers, FPT Long Chau is committed to continuing to be an extension of the health sector, accompanying partners for a healthy Vietnam; ensuring compliance with the criteria of advising on the right medicine - right disease - right dose, contributing to improving treatment compliance and comprehensive health care.

Source: https://nhandan.vn/cap-nhat-buoc-tien-y-hoc-3-trong-1-cho-nguoi-benh-chron-tinh-post875748.html